Tamsulosin Hydrochloride Capsule
Product Images NDC 72865-282

9 FDA label images from Xlcare Pharmaceuticals, Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 72865-282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural (Structural Formula)

Structural (Structural Formula)
Chemical structure of tamsulosin hydrochloride, showing its molecular composition including aromatic rings, sulfonamide group, and hydrochloride component.*
FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)
Line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over 36 hours after a single 0.4 mg oral dose under fasted and fed conditions in 8 subjects. The y-axis represents plasma concentration (ng/mL), while the x-axis shows time (hours). Two curves depict concentration changes under fasted (dashed line) and fed (solid line) states.*
FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

Figure 2a	Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)
A line graph titled 'Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1,' depicting mean change over treatment duration in weeks (0 to 13 plus LOCF). It compares three treatments: 0.8 mg dose, 0.4 mg dose, and placebo, showing symptom score changes on the vertical axis, with decreasing scores over time for all groups.*
FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

Figure 2b	Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)
A line graph showing the mean change from baseline in Total AUA Symptom Score (0 to 35) over a 13-week duration of treatment. The x-axis represents treatment duration in weeks, and the y-axis shows mean change in score. Three treatment groups are depicted: 0.8 mg dose, 0.4 mg dose, and placebo, each with a distinct line and markers. The data indicates a trend of decreasing symptom scores over time for both doses compared to placebo.*
FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)
A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in urine flow rate over treatment duration in weeks. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with 0.8 mg and 0.4 mg showing higher increases than placebo throughout the study period.*
FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)
A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in urine flow rate over treatment duration in weeks. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with sample sizes indicated at various points along the x-axis. The y-axis measures mean change in mL/sec, and the x-axis represents treatment duration in weeks up to LOCF (Last Observation Carried Forward). The 0.4 mg treatment initially shows the highest increase, followed by 0.8 mg and placebo.*
FDA Label Image

0.4mg-90s (0.4mg 90s)

0.4mg-90s (0.4mg 90s)
Label for Tamsulosin Hydrochloride Capsules USP 0.4 mg by XLcare Pharmaceuticals Inc. The package contains 90 oral capsules. The label includes storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc., Central Islip, NY), and distributor information (XLcare Pharmaceuticals, Inc., Lawrenceville, GA). It features a barcode and states "Rx Only."*
FDA Label Image

0.4mg-100s (0.4mg 100s)

0.4mg-100s (0.4mg 100s)
Label for Tamsulosin Hydrochloride Capsules USP 0.4 mg by XLcare Pharmaceuticals, Inc. The label indicates 100 capsules per container. Storage instructions specify 25°C with allowed excursions between 15° to 30°C, and the product is Rx only. Manufacturer is Ascent Pharmaceuticals, Inc., with XLcare Pharmaceuticals, Inc. as the labeler.*
FDA Label Image

0.4mg-500s (0.4mg 500s)

0.4mg-500s (0.4mg 500s)
Label for Tamsulosin Hydrochloride Capsules USP 0.4 mg, containing 500 capsules, labeled Rx Only. Manufactured by Ascent Pharmaceuticals, Inc., and manufactured for XLCare Pharmaceuticals, Inc. The label includes storage instructions and dosage reference, with NDC 72865-282-05.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.